

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A drug delivery system to a posterior segment ~~characterized in that~~ of an eye comprising fine particles containing a drug which are periorcularly subconjunctivally administered, wherein the posterior segment of the eye is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

Claim 2. (currently amended) A ~~periocular~~ subconjunctival injection which comprises fine particles containing a drug and enables the drug to ~~deliver~~ be delivered to a posterior segment of an eye, wherein the posterior segment of the eye is a retina, a choroid, an optic nerve, a vitreous body or a crystalline lens.

Claim 3. (currently amended) The drug delivery system as claimed in claim 1, wherein ~~an average~~ a particle diameter of the fine particles is 50 nm to 150 μ m.

Claim 4. (previously presented) The drug delivery system as claimed in claim 1, wherein the fine particles are made of a biodegradable or biosoluble polymer.

Claim 5. (canceled)

Claim 6. (currently amended) The drug delivery system as claimed in claim 1, wherein the drug is a drug for treatment or prevention of ~~a disease of a retina[[,]] a choroid[[,]] an optic nerve[[,]] a vitreous body or a crystalline lens~~ uveitis, cytomegalovirus retinitis, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinal detachment, pigmentary retinal degeneration, central retinal vein occlusion or central retinal artery occlusion.

Claim 7. (currently amended) The drug delivery system as claimed in claim 1, wherein the drug is an anti-inflammatory drug, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrovial or an antifungal agent.

Claim 8. (currently amended) A method of treating and/or preventing a disease of a posterior segment of an eye comprising administering ~~periocularly~~ subconjunctivally to a patient an effective amount for treatment of an injection comprising fine particles containing a drug, wherein the disease of the posterior segment of the eye is uvetis, cytomegalovirus retinitis, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinal detachment, pigmentary retinal degeneration, central retinal vein occlusion or central retinal artery occlusion.

Claim 9. (currently amended) The method of treating and/or preventing the disease of the posterior segment of the eye as

claimed in claim 8, wherein ~~an average~~ a particle diameter of the fine particles is 50 nm to 150 μ m.

Claim 10. (currently amended) The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a biodegradable or biosoluble polymer.

Claim 11. (canceled)

Claim 12. (currently amended) The method of treating and/or preventing the disease of the posterior segment of the eye as claimed in claim 8, wherein the drug is an anti-inflammatory drug, an immunosuppressor, an antiviral, an anticancer drug, an angiogenesis inhibitor, an antithrombotic agent, an optic neural protectant, an antimicrobial or an antifungal agent.

Claim 13. (currently amended) The ~~periocular~~ subconjunctival injection as claimed in claim 2, wherein ~~an average~~ a particle diameter of the fine particles is 50 nm to 150 μ m.

Claim 14. (currently amended) The periocular
subconjunctival injection as claimed in claim 2, wherein the fine
particles are made of a biodegradable or biosoluble polymer.

Claim 15. (canceled)

Claim 16. (currently amended) The periocular
subconjunctival injection as claimed in claim 2, wherein the drug
is a drug for treatment or prevention of ~~a disease of a~~
~~retina[[,]] a choroid[[,]] an optic nerve[[,]] a vitreous body or~~
~~a crystalline lens~~ uvetis, cytomegalovirus retinitis, age-related
macular degeneration, diabetic retinopathy, proliferative
vitreoretinopathy, retinal detachment, pigmentary retinal
degeneration, central retinal vein occlusion or central retinal
occlusion.

Claim 17. (currently amended) The periocular
subconjunctival injection as claimed in claim 2, wherein the drug
is an anti-inflammatory drug, an immunosuppressor, an antiviral,
an anticancer drug, an angiogenesis inhibitor, an antithrombotic
agent, an optic neural protectant, an antimicrobial or an
antifungal agent.